MCID: RSP006
MIFTS: 57

Respiratory System Disease

Categories: Respiratory diseases

Aliases & Classifications for Respiratory System Disease

MalaCards integrated aliases for Respiratory System Disease:

Name: Respiratory System Disease 12 15 17
Abnormality of the Respiratory System 29 6
Respiratory Tract Diseases 72
Respiration Disorders 72

Classifications:



External Ids:

Disease Ontology 12 DOID:1579
ICD9CM 35 510-519.99 519
ICD10 33 10 J96-J99 J98
UMLS 72 C0029582 C0035204 C0035242

Summaries for Respiratory System Disease

Disease Ontology : 12 A disease of anatomical entity that located in the respiratory system which extends from the nasal sinuses to the diaphragm.

MalaCards based summary : Respiratory System Disease, also known as abnormality of the respiratory system, is related to upper respiratory tract disease and bronchitis, and has symptoms including dyspnea, edema and respiratory distress. An important gene associated with Respiratory System Disease is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ciprofloxacin and Penicillin G have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and colon, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Related Diseases for Respiratory System Disease

Diseases related to Respiratory System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 223)
# Related Disease Score Top Affiliating Genes
1 upper respiratory tract disease 32.8 TNF RNASE3 IL6 IL5 IL4 IL13
2 bronchitis 31.6 TNF RNASE3 IL5 CXCL8
3 lung disease 31.3 TNF RNASE3 IL6 IL5 IL13 EGFR
4 cytokine deficiency 31.3 IL5 IL13
5 hypereosinophilic syndrome 31.0 RNASE3 IL5 IL4 IL13
6 rhinitis 31.0 RNASE3 IL5 IL4 IL13 CXCL8
7 allergic rhinitis 31.0 RNASE3 IL5 IL4 IL13 CXCL8
8 pneumoconiosis 30.9 TNF IL6 CXCL8
9 idiopathic interstitial pneumonia 30.9 IL4 IL13 CXCL8
10 nickel allergic contact dermatitis 11.1 IL5 IL4 IL13
11 scleritis 11.1 TNF IL5 IL4
12 angiostrongyliasis 11.1 IL5 IL4 IL13
13 bagassosis 11.1 IL6 IL5 CXCL8
14 tungiasis 11.1 TNF IL4 CXCL8
15 apple allergy 11.1 IL5 IL4 IL13
16 eosinophilic meningitis 11.1 IL5 IL4 IL13
17 polyclonal hypergammaglobulinemia 11.1 IL6 CD8A CD4
18 eosinophilic gastritis 11.1 IL5 IL4 IL13
19 paragonimiasis 11.1 RNASE3 IL5 IL13
20 chronic tic disorder 11.1 IL5 IL4 IL13
21 intestinal schistosomiasis 11.1 IL5 IL4 IL13
22 cough variant asthma 11.1 RNASE3 IL5 IL4
23 streptococcal toxic-shock syndrome 11.1 TNF IL6 CXCL8
24 ascaris lumbricoides infection 11.1 IL6 IL5 IL13
25 milk allergy 11.1 RNASE3 IL5 IL4
26 pustulosis palmaris et plantaris 11.1 TNF IL5 CCR6
27 atopic keratoconjunctivitis 11.1 RNASE3 IL5 IL4
28 opisthorchiasis 11.1 TNF IL4 CXCL8
29 cow milk allergy 11.1 TNF RNASE3 IL5
30 intrinsic asthma 11.1 RNASE3 IL5 IL4
31 papillary conjunctivitis 11.1 IL6 IL4 CXCL8
32 xanthogranulomatous cholecystitis 11.1 SERPINA3 CD8A CD4
33 angioimmunoblastic lymphadenopathy with dysproteinemia 11.1 TNF IL6 IL5 IL13
34 enterobiasis 11.1 IL5 IL4 IL13
35 autoimmune gastritis 11.1 TNF IL6 IL4 EGFR
36 stromal keratitis 11.1 TNF IL6 CCR6
37 inflammatory bowel disease 4 11.1 RNASE3 IL5 IL4 IL13
38 giant papillary conjunctivitis 11.1 RNASE3 IL4 CXCL8
39 latex allergy 11.1 RNASE3 IL5 IL4 IL13
40 chronic conjunctivitis 11.1 RNASE3 IL5 IL4 IL13
41 kimura disease 11.1 RNASE3 IL5 IL4
42 vernal keratoconjunctivitis 11.1 RNASE3 IL5 IL4 IL13
43 urinary schistosomiasis 11.1 RNASE3 IL5 IL4 IL13
44 mycoplasma pneumoniae pneumonia 11.1 TNF IL6 IL4 IL13
45 meningitis 11.1 TNF IL6 CXCL8
46 cutaneous leishmaniasis 11.1 TNF IL5 IL4 IL13
47 leishmaniasis 11.1 TNF IL5 IL4 IL13
48 status asthmaticus 11.1 RNASE3 IL5 CXCL8
49 meconium aspiration syndrome 11.1 TNF IL6 CXCL8
50 eales disease 11.1 TNF IL6 IL4

Comorbidity relations with Respiratory System Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Heart Disease Hypertension, Essential
Respiratory Failure

Graphical network of the top 20 diseases related to Respiratory System Disease:



Diseases related to Respiratory System Disease

Symptoms & Phenotypes for Respiratory System Disease

UMLS symptoms related to Respiratory System Disease:


dyspnea, edema, respiratory distress, apnea, hemoptysis, cyanosis, stridor, wheezing, rhinorrhea, inspiratory stridor, sore throat, cheyne-stokes respiration, coughing, hoarseness, anoxemia, labored breathing, expiratory wheeze, inspiratory wheeze, choking sensation, pathological conditions, signs and symptoms, signs and symptoms of ill-defined conditions, pleuritic pain, sinus congestion, other symptoms involving respiratory system and chest, bronchorrhea, neonatal cyanosis, gasping for breath, symptoms involving respiratory system and other chest symptoms, nasal congestion (finding), nasal irritation, neck tightness, larynx pain

MGI Mouse Phenotypes related to Respiratory System Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.86 CD4 EGFR IL13 IL4 IL5 IL6
2 endocrine/exocrine gland MP:0005379 9.81 ALK CD4 CD8A EGFR IL13 IL4
3 integument MP:0010771 9.61 ALK CD4 CD8A EGFR IL13 IL4
4 respiratory system MP:0005388 9.23 ALK EGFR IL13 IL4 IL5 IL6

Drugs & Therapeutics for Respiratory System Disease

Drugs for Respiratory System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 315)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
3
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
4
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
5
Nitric Oxide Approved Phase 4 10102-43-9 145068
6
Azithromycin Approved Phase 4 83905-01-5 447043 55185
7
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
8
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
9
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
10
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
11
Polyestradiol phosphate Approved Phase 4 28014-46-2
12
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
13
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
14
Ofloxacin Approved Phase 4 82419-36-1 4583
15
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
16
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
17
Clarithromycin Approved Phase 4 81103-11-9 84029
18
Tazobactam Approved Phase 4 89786-04-9 123630
19
Piperacillin Approved Phase 4 66258-76-2 43672
20
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
21
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
22
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
23
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
24
Omalizumab Approved, Investigational Phase 4 242138-07-4
25
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
26 Cytochrome P-450 CYP3A Inhibitors Phase 4
27 cefuroxime axetil Phase 4
28 Penicillin G Benzathine Phase 4
29 Penicillin G Procaine Phase 4
30 Antipyretics Phase 4
31 Adrenergic beta-Agonists Phase 4
32 Adrenergic beta-2 Receptor Agonists Phase 4
33 Bronchodilator Agents Phase 4
34 Tocolytic Agents Phase 4
35 Cholinergic Antagonists Phase 4
36 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
37 Albuterol Phase 4
38
Glycopyrrolate Phase 4 596-51-0 3494
39 Adjuvants, Anesthesia Phase 4
40 Muscarinic Antagonists Phase 4
41 Bromides Phase 4
42 Anti-Inflammatory Agents Phase 4
43 Anti-Infective Agents Phase 4
44 Contraceptives, Oral Phase 4
45 Contraceptive Agents Phase 4
46 Contraceptives, Oral, Combined Phase 4
47 Norgestimate, ethinyl estradiol drug combination Phase 4
48 Topoisomerase Inhibitors Phase 4
49 Estradiol 3-benzoate Phase 4
50 Estradiol 17 beta-cypionate Phase 4

Interventional clinical trials:

(show top 50) (show all 375)
# Name Status NCT ID Phase Drugs
1 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
2 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
3 CPAP Application at Delivery Room at Very Low Birth Weight Infants Unknown status NCT01024361 Phase 4
4 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? Unknown status NCT02171338 Phase 4
5 The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases Completed NCT01867281 Phase 4 aspirin
6 Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS) Completed NCT01443845 Phase 4 Roflumilast;Placebo
7 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients With Cough and Sputum as the Main Symptoms Completed NCT03334916 Phase 4 YMC026;Placebo
8 The Efficacy and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine Completed NCT02477293 Phase 4 Hyeonggaeyeongyo-tang
9 The Effect of Supplemental Oxygen During Physical Exercise Training on Exercise Capacity in COPD Patients. Completed NCT01150383 Phase 4
10 Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease Completed NCT02079701 Phase 4
11 Feedback Reports and E-learning to Support Spirometry Test Performance in Dutch Family Practices Completed NCT00962455 Phase 4
12 Small Particle Inhaled Steroids in Refractory Steroid-responsive Asthma Completed NCT01171365 Phase 4 Ciclesonide;Placebo
13 A Randomized, Double-blind, Parallel Group, 26-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 Given Once or Twice Daily, in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease Completed NCT02371629 Phase 4 NVA237;Placebo;Salbutamol
14 Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Rates of Fever After 2013-2014 Inactivated Influenza Vaccine (IIV) in Young Children Completed NCT01946594 Phase 4
15 Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Recruiting NCT03540901 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
16 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Recruiting NCT02735707 Phase 4 Hydrocortisone;Ceftriaxone;Moxifloxacin or Levofloxacin;Piperacillin tazobactam;Ceftaroline;Amoxicillin Clavulanate;Macrolide administered for 3 days;Macrolide administered for up to 14 days
17 Non-specific Effects of Rabies Vaccine on the Incidence of Common Infectious Disease Episodes: a Randomized Controlled Trial Enrolling by invitation NCT03656198 Phase 4 Sterile Water Injection
18 Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Treatment With Omalizumab Terminated NCT00784485 Phase 4 Xolair injections
19 Efficacy of Vitamin D on the Clinical Management of Pediatric Patients With Asthma in the Hospital General Naval de Alta Especialidad Unknown status NCT02571660 Phase 3 GINA treatment fot asthma +vit.D low supplementation dose;GINA treatment fot asthma +vit.D high supplementation dose
20 Effect of the Preoperative Administration of Dexamethasone in the Respiratory Function and Postoperative Symptoms in Women Undergoing Mastectomy for Cancer. Results of a Randomized Clinical Trial. Unknown status NCT02305173 Phase 3 Intravenous Dexamethasone;intravenous salin water
21 A Multicenter, Non-Randomized, Open Label Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases In Japan Adults Completed NCT00360464 Phase 3 Azithromycin SR
22 The Effect of Probiotics on Infections in Toddlers Completed NCT00823056 Phase 3
23 Validation of a Simulated Clinical Evaluation of Ventilators Completed NCT01113255 Phase 2, Phase 3
24 Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy Completed NCT00319306 Phase 3 Budesonide/formoterol
25 A Multi-Center, Multinational, Randomized, Double-Blind, Parallel Group Study of the Effects of Ciclesonide Hfa-Mdi 640 μg/Day and Beclomethasone Hfa-Mdi 640 μg/Day on Lens Opacification in Adult Subjects With Moderate to Severe Persistent Asthma Completed NCT00254956 Phase 3 ciclesonide (XRP1526)
26 A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE) Completed NCT02417961 Phase 3
27 A Multicenter, Open-Label, Functionality, Reliability and Performance Study of a Single-Use Auto-Injector With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GRECO) Completed NCT02918071 Phase 3
28 A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma Completed NCT01928771 Phase 3
29 A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA) Completed NCT01914757 Phase 3
30 A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma. Completed NCT02322775 Phase 3
31 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001 Completed NCT00382408 Phase 3
32 CSP #574 - Evaluate the Safety and Efficacy of Methylprednisolone in Hospitalized Veterans With Severe Community-Acquired Pneumonia Completed NCT01283009 Phase 3 Methylprednisolone
33 A Randomized, Placebo-Controlled Trial to Evaluate the Effects of Phenylephrine HCl 30 mg Extended-Release Tablets on Nasal Congestion in Subjects With Allergic Rhinitis Completed NCT01413958 Phase 3 Phenylephrine;Placebo;Loratadine
34 A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations. Completed NCT02155660 Phase 3 Benralizumab Arm A;Benralizumab Arm B;Benralizumab Arm C;Placebo
35 Randomised, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations Completed NCT02138916 Phase 3 Benralizumab Arm A;Benralizumab Arm B;Placebo
36 A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation Completed NCT02869438 Phase 3 Benralizumab
37 A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis Completed NCT01918033 Phase 3 Desloratadine 5 mg;Placebo
38 A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy (ZONDA) Completed NCT02075255 Phase 3
39 A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients Completed NCT01715298 Phase 3 NVA237;Placebo
40 A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients Completed NCT01709864 Phase 3 NVA237;Placebo
41 A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA) Completed NCT02258542 Phase 3
42 A Phase III Study to Assess Immunogenicity and Safety of 4th LBVH0101 Vaccination Compared With 4th Hiberix™ Vaccination in Healthy Toddlers Who Completed Primary Vaccination in LG-VHCL002 Study Completed NCT01251133 Phase 3
43 A Randomized, Controlled Phase III Trial to Evaluate the Efficacy of Elortinib vs Gefitinib in Advanced Non-small-cell Lung Cancer With EGFR Exon 19 or 21 Mutations Completed NCT01024413 Phase 3 erlotinib;gefitinib
44 Cluster-randomised, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections in Sheltered Accommodation (ViDiFlu) Completed NCT01069874 Phase 2, Phase 3
45 A Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema Completed NCT01181466 Phase 2, Phase 3
46 Intranasal Ketamine for Peripheral Venous Puncture in Pediatric Patients: A Randomized Double Blind and Placebo Controlled Study Completed NCT02929524 Phase 2, Phase 3 Ketamine;Placebo
47 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation Completed NCT00909532 Phase 3 Ivacaftor;Placebo
48 A Multicenter, Randomized Study to Compare the Safety and Efficacy of Oral Levofloxacin With Amoxicillin/Clavulanate Potassium in the Treatment of Acute Sinusitis in Adults Completed NCT00249210 Phase 3 levofloxacin
49 A Multicenter, Randomized, Open Label Study to Compare the Safety and Efficacy of Levofloxacin With That of Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia Completed NCT00236834 Phase 3 levofloxacin; imipenem/cilastitin
50 Multicenter, Double-Blind Randomized Study to Compare the Safety and Efficacy of Levofloxacin 750 mg Once Daily for Five Days vs. Levofloxacin 500 mg Once Daily for 10 Days in the Treatment of Mild to Severe Community-Acquired Pneumonia in Adults Completed NCT00236821 Phase 3 levofloxacin

Search NIH Clinical Center for Respiratory System Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Glycopyrrolate
nalmefene
Nalmefene hydrochloride
Naloxone Hydrochloride
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate
Prednisone
PREDNISONE PWDR

Genetic Tests for Respiratory System Disease

Genetic tests related to Respiratory System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Respiratory System 29

Anatomical Context for Respiratory System Disease

MalaCards organs/tissues related to Respiratory System Disease:

41
Lung, Testes, Colon, Heart, Breast, Thyroid, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Respiratory System Disease:

19
Respiratory System Which Extends From The Nasal Sinuses To The Diaphragm

Publications for Respiratory System Disease

Articles related to Respiratory System Disease:

(show top 50) (show all 56)
# Title Authors PMID Year
1
The impact of ambient particulate matter on hospital outpatient visits for respiratory and circulatory system disease in an urban Chinese population. 38
30812001 2019
2
Toxoplasma gondii in four captive kangaroos (Macropus spp.) in China: Isolation of a strain of a new genotype from an eastern grey kangaroo (Macropus giganteus). 38
30923671 2019
3
Early warning signals for critical transitions in cardiopulmonary health, related to air pollution in an urban Chinese population. 38
30219611 2018
4
Valsartan attenuates bleomycin-induced pulmonary fibrosis by inhibition of NF-κB expression and regulation of Th1/Th2 cytokines. 38
29447007 2018
5
Neighbouring green space and mortality in community-dwelling elderly Hong Kong Chinese: a cohort study. 38
28765127 2017
6
Characteristics of Traditional Chinese Medicine Use in Pediatric Cancer Patients: A Nationwide, Retrospective, Taiwanese-Registry, Population-Based Study. 38
27405933 2017
7
[Computer-aided Diagnosis and New Electronic Stethoscope]. 38
29862758 2017
8
IMPACT OF SULPHUR DIOXIDE ON THE RESPIRATORY SYSTEM OF TBILISI POPULATION. 38
28574394 2017
9
Hospital admissions for respiratory system diseases in adults with intellectual disabilities in Southeast London: a register-based cohort study. 38
28360254 2017
10
[Recent progress of IncRNA in respiratory system disease]. 38
27852369 2016
11
[Status of two-week illness for primary and secondary students in middle and west provinces]. 38
27807333 2016
12
[Application of electronic bronchoscopy in pediatric intensive care patients with difficult ventilator weaning]. 38
27530791 2016
13
Respiratory System Disease. 38
27469180 2016
14
[Analysis on causes of death of residents in Beijing, 1965-1974]. 38
27453108 2016
15
Risk Factors for Acute Kidney Injury after Cardiovascular Surgery: Evidence from 2,157 Cases and 49,777 Controls - A Meta-Analysis. 38
27275160 2016
16
The impact of PM2.5 on the human respiratory system. 38
26904255 2016
17
[Study on burden of disease in Chongqing, 2010-2013]. 38
26837360 2015
18
Fine Particulate Matter Pollution and Hospital Admissions for Respiratory Diseases in Beijing, China. 38
26402691 2015
19
Tic disorders in the differential diagnosis of chronic cough in children in relation to four cases. 38
26568694 2015
20
Preoperative FeNO as a screening indicator of pulmonary complications after abdominal surgery in patients over 60 years old. 38
25992977 2015
21
Asthma-chronic obstructive pulmonary disease overlap syndrome in Poland. Findings of an epidemiological study. 38
25610352 2014
22
[Research progress about the relationship between nanoparticles silicon dioxide and lung cancer]. 38
25342044 2014
23
Efficient post-disaster patient transportation and transfer: experiences and lessons learned in emergency medical rescue in Aceh after the 2004 Asian tsunami. 38
25102536 2014
24
Survival in systemic lupus erythematosus, 1995-2010. A prospective study in a Danish community. 38
23873432 2013
25
[Spatial distribution of inhalable particulate and association with respiratory disease in Beijing City]. 38
23487945 2013
26
[What temperature index is the best predictor for the impact of temperature on mortality]. 38
23363873 2012
27
Comparison of risk factors for recurrent respiratory infections between urban and rural preschool children in Yiwu, China. 38
22573425 2012
28
[Optimisation of diagnostics and differential diagnostics disseminated pulmonary tuberculosis]. 38
23457976 2012
29
Clinical pharmacists on medical care of pediatric inpatients: a single-center randomized controlled trial. 38
22292061 2012
30
Medical and social problems among women headed families in Baghdad. 38
25003041 2012
31
The evolution of academic performance in nine subspecialties of internal medicine: an analysis of journal citation reports from 1998 to 2010. 38
23118973 2012
32
Impact of morbidity and life events on successful aging. 38
21727083 2011
33
[Epidemiological study of women adults with mixed urinary incontinence in China]. 38
20973221 2010
34
Mortality patterns of Army Chemical Corps veterans who were occupationally exposed to herbicides in Vietnam. 38
20382334 2010
35
Epidemiology of mixed urinary incontinence in China. 38
20022321 2010
36
Indoor air pollution as a lung health hazard: focus on populous countries. 38
19532032 2009
37
[Tobacco smoking among young patients with bronchial asthma and determination of smoking-related behavior in the patient's closest environment]. 38
19603694 2009
38
Canada's global position in life expectancy: a longitudinal comparison with the healthiest countries in the world. 38
19263968 2009
39
Hypercapnia and hypocapnia in neonates. 38
18822927 2008
40
Identification of regional air pollution characteristic and the correlation with public health in Taiwan. 38
17617673 2007
41
Helicobacter pylori infection as a possible risk factor for respiratory system disease: a review of the literature. 38
16759841 2007
42
Predictors of mortality in acute renal failure in a developing country: a prospective study. 38
17497470 2007
43
Complications following D3 gastrectomy: post hoc analysis of a randomized trial. 38
16369704 2006
44
Nutritional status of patients hospitalized in pediatric clinic. 38
16547850 2005
45
[Vascular risk factors in primary open angle glaucoma]. 38
15644886 2004
46
[Pulmonary function and nutrition]. 38
15143398 2003
47
[New clinical tests that physicians should know for diagnosis of respiratory system disease]. 38
9867006 1998
48
Morbidity and mortality after radical gastrectomy for patients with carcinoma of the stomach. 38
7599767 1995
49
[Forced oscillation technique in respiratory system studies. II. Clinical interpretation of results in respiratory system diseases]. 38
8616489 1995
50
Clinical examination of the respiratory system. 38
2054703 1991

Variations for Respiratory System Disease

ClinVar genetic disease variations for Respiratory System Disease:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;t(9;14)(p21;q12)dn Translocation Uncertain significance

Expression for Respiratory System Disease

Search GEO for disease gene expression data for Respiratory System Disease.

Pathways for Respiratory System Disease

Pathways related to Respiratory System Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 TNF SERPINA3 RNASE3 KRAS IL6 IL5
2
Show member pathways
13.88 TNF KRAS IL6 IL5 IL4 IL13
3
Show member pathways
13.7 TNF KRAS IL6 IL5 IL4 IL13
4
Show member pathways
13.57 TNF KRAS IL6 IL5 IL4 IL13
5
Show member pathways
13.4 TNF KRAS IL6 IL5 IL4 IL13
6
Show member pathways
13.4 TNF KRAS IL6 IL5 IL4 IL13
7
Show member pathways
13.31 TNF KRAS IL6 IL5 IL4 IL13
8
Show member pathways
12.98 TNF KRAS IL6 EGFR CXCL8 CD4
9 12.86 KRAS IL6 IL5 IL4 IL13 EGFR
10
Show member pathways
12.7 TNF RNASE3 IL6 IL5 IL4 IL13
11
Show member pathways
12.64 TNF IL6 IL5 IL4 IL13 CD4
12
Show member pathways
12.61 TNF KRAS IL6 EGFR CD4
13
Show member pathways
12.6 TNF KRAS IL5 IL4 IL13
14
Show member pathways
12.58 TNF KRAS IL6 IL5 IL4 CD8A
15 12.56 MIR34C MIR21 MIR145 MIR126 MIR125A KRAS
16
Show member pathways
12.46 KRAS IL6 IL5 IL4 IL13 EGFR
17
Show member pathways
12.44 KRAS IL5 IL13 EGFR
18
Show member pathways
12.39 TNF IL6 IL5 IL4 IL13 CXCL8
19
Show member pathways
12.34 TNF SERPINA3 IL6 IL4
20 12.31 TNF MIR21 KRAS EGFR
21
Show member pathways
12.24 TNF IL6 EGFR CXCL8
22 12.21 TNF KRAS IL6 EGFR
23
Show member pathways
12.2 TNF IL6 IL4 CXCL8
24 12.19 TNF IL6 IL13 CXCL8
25
Show member pathways
12.18 TNF KRAS IL6 IL5 IL4 IL13
26 12.08 TNF IL6 IL4 EGFR CXCL8
27
Show member pathways
12.07 TNF IL6 IL4 IL13
28 12.05 TNF IL6 IL4 IL13 CXCL8
29
Show member pathways
12.05 KRAS IL6 IL5 IL4 IL13 EGFR
30 12 TNF IL6 IL5 IL4 CD8A CD4
31 11.96 TNF KRAS IL6 CXCL8
32 11.88 IL6 IL5 IL4 IL13 CXCL8
33 11.87 TNF IL6 IL5 IL4 CD8A CD4
34 11.86 TNF IL6 CXCL8
35
Show member pathways
11.83 TNF IL5 IL4 CXCL8
36 11.82 TNF IL6 CD8A CD4
37 11.79 TNF IL6 IL4 IL13
38 11.77 TNF IL6 CXCL8
39 11.75 KRAS EGFR CXCL8
40 11.69 IL6 EGFR CXCL8
41
Show member pathways
11.68 TNF IL6 CXCL8
42 11.62 TNF IL6 CXCL8
43 11.58 TNF IL6 EGFR
44 11.57 IL5 IL4 IL13 CD4
45 11.57 TNF IL6 IL4 IL13 CXCL8
46 11.56 TNF IL6 CXCL8
47 11.54 TNF KRAS EGFR
48 11.43 TNF IL6 IL5 IL4 IL13 CXCL8
49 11.4 TNF IL5 IL4 IL13 CD8A CD4
50 11.28 TNF IL6 IL5 IL4 IL13 CXCL8

GO Terms for Respiratory System Disease

Cellular components related to Respiratory System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 TNF SERPINA3 RNASE3 IL6 IL5 IL4
2 membrane raft GO:0045121 9.56 TNF KRAS EGFR CD4
3 external side of plasma membrane GO:0009897 9.43 TNF IL13 ICOSLG CD8A CD4 CCR6
4 extracellular space GO:0005615 9.4 TNF SERPINA3 RNASE3 MIR21 MIR126 MIR125A

Biological processes related to Respiratory System Disease according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.93 TNF KRAS IL5 EGFR
2 inflammatory response GO:0006954 9.91 TNF SERPINA3 IL6 IL5 IL13 CXCL8
3 positive regulation of protein kinase B signaling GO:0051897 9.87 TNF MIR21 MIR126 EGFR
4 cellular response to lipopolysaccharide GO:0071222 9.86 TNF MIR21 IL6 CXCL8
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 IL6 IL5 CD4
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 TNF KRAS IL6 ALK
7 defense response to Gram-negative bacterium GO:0050829 9.83 RNASE3 IL6 CD4
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.82 TNF IL6 EGFR
9 positive regulation of inflammatory response GO:0050729 9.82 TNF MIR21 EGFR
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 TNF MIR21 MIR126
11 positive regulation of gene expression GO:0010628 9.8 TNF MIR21 MIR125A KRAS IL6 IL4
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 IL6 IL4 IL13
13 response to glucocorticoid GO:0051384 9.79 TNF KRAS IL6
14 positive regulation of MAP kinase activity GO:0043406 9.78 TNF KRAS EGFR
15 positive regulation of T cell proliferation GO:0042102 9.77 IL6 IL4 CD4
16 humoral immune response GO:0006959 9.77 TNF IL6 CCR6
17 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.76 EGFR CD8A CD4 ALK
18 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.72 TNF MIR21 MIR126 EGFR CD4
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.71 TNF IL6 IL13 EGFR
20 positive regulation of B cell proliferation GO:0030890 9.7 IL5 IL4 IL13
21 positive regulation of MAPK cascade GO:0043410 9.69 MIR126 IL6 CD4
22 negative regulation of endothelial cell apoptotic process GO:2000352 9.67 MIR126 IL4 IL13
23 T cell activation GO:0042110 9.67 IL4 ICOSLG CD8A CD4
24 positive regulation of podosome assembly GO:0071803 9.65 TNF IL5
25 positive regulation of immunoglobulin secretion GO:0051024 9.65 IL6 IL5
26 astrocyte activation GO:0048143 9.64 TNF EGFR
27 negative regulation of lipid storage GO:0010888 9.62 TNF IL6
28 immune response GO:0006955 9.61 TNF IL6 IL5 IL4 IL13 CXCL8
29 positive regulation of neuroinflammatory response GO:0150078 9.58 TNF IL6
30 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.58 TNF MIR21
31 positive regulation of protein phosphorylation GO:0001934 9.55 TNF MIR21 KRAS EGFR CD4
32 negative regulation of complement-dependent cytotoxicity GO:1903660 9.48 IL4 IL13
33 cytokine-mediated signaling pathway GO:0019221 9.23 TNF KRAS IL6 IL5 IL4 IL13
34 positive regulation of transcription, DNA-templated GO:0045893 10.02 TNF IL6 IL5 IL4 EGFR CD4

Molecular functions related to Respiratory System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.46 MIR21 MIR145 MIR126 MIR125A
2 RNA polymerase II complex binding GO:0000993 9.13 MIR145 MIR126 MIR125A
3 cytokine activity GO:0005125 9.1 TNF IL6 IL5 IL4 IL13 CXCL8

Sources for Respiratory System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....